FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis

By on    Pharma Industry News  

FDA approves Arcutis Biotherapeutics’ ZORYVE for pediatric and adult atopic dermatitis

In a significant development for the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream, 0.15%, for patients aged six years and older. This approval marks a pivotal advancement in immuno-dermatology, offering a steroid-free, once-daily cream that targets mild to moderate […]

Arcutis Biotherapeutics gets ZORYVE FDA approval for seborrheic dermatitis

By on    Pharma Industry News  

Arcutis Biotherapeutics gets ZORYVE FDA approval for seborrheic dermatitis

Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration’s (FDA) approval of their new drug application for ZORYVE (roflumilast) topical foam, 0.3%, aimed at treating seborrheic dermatitis in individuals aged 9 years and older. This approval marks a significant advancement in dermatological care, with ZORYVE being the first drug […]